HF Advisory Group LLC Sells 675 Shares of McKesson Corporation $MCK

HF Advisory Group LLC reduced its position in shares of McKesson Corporation (NYSE:MCK) by 30.8% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,516 shares of the company’s stock after selling 675 shares during the period. HF Advisory Group LLC’s holdings in McKesson were worth $1,146,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. University of Texas Texas AM Investment Management Co. acquired a new stake in shares of McKesson during the fourth quarter worth approximately $25,000. Swiss RE Ltd. bought a new position in McKesson in the 4th quarter valued at $26,000. State of Wyoming bought a new position in McKesson in the 2nd quarter valued at $29,000. Kingdom Financial Group LLC. acquired a new position in McKesson in the fourth quarter worth $33,000. Finally, Birchwood Financial Partners Inc. bought a new stake in shares of McKesson during the fourth quarter worth $33,000. 85.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. UBS Group upped their price target on shares of McKesson from $1,050.00 to $1,080.00 and gave the stock a “buy” rating in a research report on Thursday. Morgan Stanley reaffirmed an “overweight” rating on shares of McKesson in a research note on Friday. Wall Street Zen cut shares of McKesson from a “buy” rating to a “hold” rating in a research note on Saturday, June 27th. Barclays decreased their price objective on shares of McKesson from $1,050.00 to $925.00 and set an “overweight” rating for the company in a report on Wednesday, June 10th. Finally, William Blair started coverage on McKesson in a research report on Tuesday, April 28th. They issued an “outperform” rating for the company. Fourteen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $968.93.

Insiders Place Their Bets

In other news, CAO Napoleon B. Rutledge, Jr. sold 133 shares of the business’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $764.00, for a total transaction of $101,612.00. Following the sale, the chief accounting officer directly owned 632 shares in the company, valued at approximately $482,848. The trade was a 17.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Thomas L. Rodgers sold 699 shares of the firm’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $735.27, for a total transaction of $513,953.73. Following the completion of the transaction, the executive vice president owned 2,268 shares of the company’s stock, valued at approximately $1,667,592.36. This trade represents a 23.56% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 28,748 shares of company stock valued at $22,262,035. 0.06% of the stock is owned by corporate insiders.

McKesson Stock Up 0.0%

NYSE:MCK opened at $871.72 on Friday. McKesson Corporation has a 12-month low of $637.00 and a 12-month high of $999.00. The stock’s 50 day moving average price is $800.68 and its two-hundred day moving average price is $840.98. The firm has a market capitalization of $101.63 billion, a price-to-earnings ratio of 23.33, a P/E/G ratio of 1.43 and a beta of 0.30.

McKesson (NYSE:MCK) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $9.93 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $9.56 by $0.37. The company had revenue of $105.38 billion during the quarter, compared to analysts’ expectations of $103.88 billion. McKesson had a negative return on equity of 253.21% and a net margin of 1.12%.The business’s revenue was up 7.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $8.26 earnings per share. McKesson has set its FY 2027 guidance at 44.200-45.000 EPS. Equities research analysts expect that McKesson Corporation will post 44.59 EPS for the current year.

McKesson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 1st. Investors of record on Tuesday, September 1st will be given a dividend of $0.94 per share. The ex-dividend date is Tuesday, September 1st. This represents a $3.76 annualized dividend and a dividend yield of 0.4%. This is a positive change from McKesson’s previous quarterly dividend of $0.82. McKesson’s dividend payout ratio (DPR) is 10.06%.

Key Stories Impacting McKesson

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: Quarterly results exceeded expectations. McKesson reported adjusted earnings of $9.93 per share, ahead of the $9.44-$9.56 analyst consensus range, while revenue rose 7.7% year over year to $105.38 billion, topping estimates. EPS also increased from $8.26 in the prior-year quarter. McKesson Q1 Earnings and Revenues Top Estimates
• Positive Sentiment: Specialty pharmaceutical growth drove profitability. Pharma profit rose 19%, supported by specialty medicine demand and oncology growth. Management raised fiscal 2027 adjusted EPS guidance to $44.20-$45.00, broadly in line with or above current analyst expectations. MCK Q1 Earnings Call Centers on Pharma-Led Guidance Raise
• Positive Sentiment: Capital returns are becoming more attractive. McKesson plans approximately $5 billion in share repurchases and raised its dividend by 15%, potentially supporting per-share earnings and investor sentiment. McKesson Outlines Fiscal 2027 EPS and Share Repurchases
• Neutral Sentiment: McKesson is rebranding its Medical-Surgical Solutions business as Wellverse ahead of a planned spinoff and potential IPO. The move could unlock value, although it also introduces execution and separation risks. McKesson Debuts Wellverse Name
• Neutral Sentiment: Recent Zacks commentary characterizes MCK as a growth stock, citing earnings growth, specialty-drug exposure and improving fundamentals. However, these articles are analytical opinions rather than new company announcements. McKesson Is an Incredible Growth Stock

McKesson Company Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.